Senior Clinical Researcher
His research interests focus on the development of new drugs to treat breast cancer and he is principal and chief investigator on several clinical trials of novel therapies. Additionally, he has led a number of clinical studies assessing how novel metabolic imaging signatures may reflect tumour biology.
Simon Lord has been Senior Clinical Researcher in Experimental Cancer Therapeutics in the Department of Oncology since 2015 and is a consultant medical oncologist at the Oxford Cancer Centre. He undertook his medical oncology training in Leeds before moving to Oxford to pursue his DPhil and take up a Cancer Research UK Clinical Research Fellowship. He is an Against Breast Cancer Fellow at Oriel College and is a module lead for the Precision Cancer Medicine MSc at the University of Oxford.
Morotti M. et al, (2019), Proc Natl Acad Sci U S A
A Phase I dose-finding and safety study of AZD8931 with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma: the randomised expansion phase of the DEBIOC trial
Thomas A. et al, (2018)
Lord SR. et al, (2018), Cell Metab, 28, 679 - 688.e4
Morotti M. et al, (2018), Eur J Drug Metab Pharmacokinet, 43, 137 - 153
Fluciclovine is a potential imaging biomarker of glutamine utilisation in breast cancer
Teoh EJ. et al, (2017), EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 44, S633 - S634